News

Indian Medical Device Industry Faces Major Setback as US Tariffs Take Effect, Hopes for Diplomatic Resolution

The new tariff policy, which took immediate effect, marks a significant shift from previous trade terms under which Indian medical devices entered the U.S. market with a minimal duty of 0-7.5%. This abrupt change is expected to challenge Indian manufacturers, many of whom have built competitive advantages in producing cost-effective, high-quality medical devices.

• By Newsdesk
• New Delhi
• Apr 03, 2025

News

The recent imposition of a 27% tariff on medical device imports by the U.S. has sent shockwaves through India’s medical technology sector, raising concerns about trade disruptions, increased costs, and restricted access to a crucial market. Announced as part of the U.S. administration’s strategy to enforce trade reciprocity and prioritize domestic manufacturing, the move has sparked apprehension among industry stakeholders in India.

The new tariff policy, which took immediate effect, marks a significant shift from previous trade terms under which Indian medical devices entered the U.S. market with a minimal duty of 0-7.5%. This abrupt change is expected to challenge Indian manufacturers, many of whom have built competitive advantages in producing cost-effective, high-quality medical devices.

Industry leaders have voiced their concerns over the impact of the tariff, emphasizing that such protectionist measures could hinder global trade dynamics. “The decision to impose reciprocal tariffs does not reflect informed policymaking. While intended to protect domestic industries, it may inadvertently stifle the principles of free and fair trade that benefit both nations,” said Pavan Choudary, Chairman of the Medical Technology Association of India (MTaI).

Rajiv Nath, a key industry figure, pointed out that while the move would bolster U.S. manufacturers by increasing capacity utilization and expanding their market share, it could also prompt a reversal of investments in certain product segments where Indian companies currently enjoy a natural advantage. Products such as low-risk, high-volume consumables and disposables, which had previously seen production shift to India, may witness renewed investment in U.S.-based manufacturing.

The medical devices trade between the two countries has historically been skewed in favor of the U.S., with India exporting medical devices worth $714.38 million (approximately ₹614 crore) to the U.S. in FY 2023-24, while imports from the U.S. stood at more than double, totaling $1,519.94 million (around ₹1,300 crore), according to the Export Promotion Council of Medical Devices.

Despite the concerns raised, the White House has justified the move by highlighting what it describes as India’s “uniquely burdensome and duplicative testing and certification requirements” in the medical devices sector. According to a White House factsheet, “If these barriers were removed, U.S. exports would increase by at least $5.3 billion annually.”

Interestingly, while medical devices have been subjected to tariffs, sectors such as pharmaceuticals and semiconductors have been granted exemptions. Industry experts are advocating for a balanced approach through bilateral negotiations rather than escalating trade restrictions. They argue that both nations should adopt a strategic, cooperative framework rather than resorting to protectionist policies.

Amidst these developments, India’s Commerce and Industry Minister, Piyush Goyal, reassured stakeholders of the country’s commitment to reducing trade barriers. Addressing the ongoing Budget session in the Lok Sabha, he stated, “With the changing trade scenario, India is moving towards free trade agreements wherein customs tariffs and non-tariff barriers are reduced or eliminated on substantial trade.”

As India navigates these new trade challenges, diplomatic engagements will be crucial in determining whether a more favorable resolution can be achieved to safeguard the interests of its medical device industry.